BioSpace News Archive

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to 3 new employees.

On September 28, 2022, AVITA Medical, Inc. appointed Jim Corbett as Chief Executive Officer, effective immediately. Mr. Corbett, who has served as a non-executive member of the Board of Directors, will continue as an executive member of the Board of Directors of AVITA Medical, Inc.

Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO™ New Drug Submission (NDS).

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental Biologics License Application (sBLA) to add a Monday/Wednesday/Friday (MWF) intramuscular (IM) dosing schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical” or the “Company”) today announced its financial results and provided a business update for the six months ended June 30, 2022.

The company announced the first phase of the set of in vitro experiments designed to accomplish this validation was successful.

Novavax, Inc. (Nasdaq: NVAX) today announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous booster in adults aged 18 and older.

HiFiBiO Therapeutics announced today a second clinical trial supply agreement with Novartis to evaluate HiFiBiO’s HFB200603, a novel anti-BLTA monoclonal antibody in combination with tislelizumab, Novartis anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug Intelligence Science (DIS™) platform.